======= PHF8 ======= == Gene Information == * **Official Symbol**: PHF8 * **Official Name**: PHD finger protein 8 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=23133|23133]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q9UPP1|Q9UPP1]] * **Interactions**: [[https://thebiogrid.org/search.php?search=PHF8&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PHF8|Open PubMed]] * **OMIM**: [[https://omim.org/entry/300560|Open OMIM]] == Function Summary == * **Entrez Summary**: The protein encoded by this gene is a histone lysine demethylase that preferentially acts on histones in the monomethyl or dimethyl states. The encoded protein requires Fe(2+) ion, 2-oxoglutarate, and oxygen for its catalytic activity. The protein has an N-terminal PHD finger and a central Jumonji C domain. This gene is thought to function as a transcription activator. Defects in this gene are a cause of syndromic X-linked Siderius type intellectual disability (MRXSSD) and over-expression of this gene is associated with several forms of cancer. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2017]. * **UniProt Summary**: N/A |JmjC| |PHD| |histone H4-K20 demethylation| |negative regulation of chromatin silencing at rDNA| |histone demethylase activity (H4-K20 specific)| |regulation of chromatin silencing at rDNA| |histone demethylase activity (H3-K27 specific)| |histone H3-K27 demethylation| |histone H3-K36 demethylation| |histone demethylase activity (H3-K36 specific)| |histone demethylase activity (H3-K9 specific)| |histone demethylase activity| |histone H3-K9 demethylation| |2-oxoglutarate-dependent dioxygenase activity| |negative regulation of chromatin silencing| |positive regulation of transcription by RNA polymerase I| |histone lysine demethylation| |histone demethylation| |protein dealkylation| |protein demethylation| |regulation of transcription by RNA polymerase I| |negative regulation of gene silencing| |regulation of chromatin silencing| |negative regulation of chromatin organization| |methylated histone binding| |positive regulation of gene expression, epigenetic| |demethylation| |G1/S transition of mitotic cell cycle| |cell cycle G1/S phase transition| |regulation of gene silencing| |iron ion binding| |negative regulation of chromosome organization| |regulation of chromatin organization| |regulation of gene expression, epigenetic| |nuclear membrane| |mitotic cell cycle phase transition| |cell cycle phase transition| |regulation of chromosome organization| |histone modification| |negative regulation of organelle organization| |covalent chromatin modification| |chromatin binding| |mitotic cell cycle process| |mitotic cell cycle| |chromatin organization| |negative regulation of cellular component organization| |brain development| |head development| |zinc ion binding| |nucleolus| |oxidation-reduction process| |central nervous system development| |cell cycle process| |chromosome organization| |regulation of organelle organization| |cell cycle| |positive regulation of transcription, DNA-templated| |positive regulation of nucleic acid-templated transcription| |positive regulation of RNA biosynthetic process| |positive regulation of RNA metabolic process| |positive regulation of nucleobase-containing compound metabolic process| |positive regulation of macromolecule biosynthetic process| |positive regulation of cellular biosynthetic process| |positive regulation of gene expression| |positive regulation of biosynthetic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-2.46| |[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|-2.04| |[[:results:exp184|Ixabepilone 0.004 to 0.005μM on day4 R04 exp184]]|-1.98| |[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|-1.96| |[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|-1.95| |[[:results:exp67|BVD-523 15μM R02 exp67]]|-1.83| |[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|-1.78| |[[:results:exp354|Diepoxybutane 3μM R07 exp354]]|-1.77| |[[:results:exp288|HMS-I2 10μM R06 exp288]]|1.7| |[[:results:exp531|THZ1 0.06μM R08 exp531]]|1.73| |[[:results:exp301|VER-155008 3.9μM R06 exp301]]|1.79| |[[:results:exp318|ABT-702 5μM R07 exp318]]|1.97| |[[:results:exp439|QNZ 0.01μM R08 exp439]]|2.2| ^Gene^Correlation^ |[[:human genes:h:hgc6.3|HGC6.3]]|0.46| |[[:human genes:u:ube2q1|UBE2Q1]]|0.426| Global Fraction of Cell Lines Where Essential: 0/683 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/26| |bone|0/25| |breast|0/30| |central nervous system|0/49| |cervix|0/4| |colorectal|0/17| |esophagus|0/11| |fibroblast|0/1| |gastric|0/14| |kidney|0/18| |liver|0/19| |lung|0/72| |lymphocyte|0/14| |ovary|0/25| |pancreas|0/22| |peripheral nervous system|0/15| |plasma cell|0/12| |prostate|0/1| |skin|0/20| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/28| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 10263 * **Expression level (log2 read counts)**: 5.99 {{:chemogenomics:nalm6 dist.png?nolink |}}